drugset / Trial / NCT06979336

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336 ↗

Phase 2 Recruiting 224 enrolled Genentech, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of RO7837195 compared with placebo in participants with moderately to severely active ulcerative colitis for whom prior treatment with conventional and/or advanced therapies has failed.

Timeline

Start
2025-09-29
Primary completion
2027-08-25
Completion
2028-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RO7837195 Unknown — —

Indications